New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PMFG;FB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 15, 2014
06:10 EDTFBFacebook implied volatility of 30 at lower end of index mean range
Subscribe for More Information
06:06 EDTFBFacebook stops including results from Bing on site, Reuters reports
A Facebook (FB) spokesperson has confirmed that the company has stopped including results from Microsoft’s (MSFT) Bing search engine on its site as it has revamped its own search offerings, Reuters reported on Friday. Facebook recently introduced a tool that allows users to quickly find past comments and other information posted by their friends on the social networking site. The spokesperson comments that "We continue to have a great partnership with Microsoft in lots of different areas." Reference Link
December 12, 2014
16:00 EDTFBOptions Update; December 12, 2014
Subscribe for More Information
09:35 EDTFBActive equity options trading
Subscribe for More Information
December 11, 2014
13:57 EDTFBFacebook using contact info to measure ad effectiveness, Wired says
Facebook is measuring how much its ads influence shoppers by comparing phone numbers and e-mails collected in stores with the phone numbers and e-mail addresses on Facebook accounts, Wired quoted Brian Boland, the vice president of ad tech at Facebook,as saying. Reference Link
10:38 EDTFBFacebook holds a webcast
Facebook holds a live Q&A webcast with Mark Zuckerberg on December 11 at 5 pm. Webcast Link
08:54 EDTFBFacebook management to meet with UBS
Meeting to be held in London on December 11 hosted by UBS.
08:53 EDTFBBritain lays out details for proposed 25% 'Google Tax,' WSJ reports
U.S. technology giants such as Google (GOOGL, GOOG), Facebook (FB), Microsoft (MSFT) and Apple (AAPL) have come under fire in Britain for the relatively small corporate taxes they pay there and the U.K. government detailed plans for a new 25% tax on profits of multinational technology and other companies, reported The Wall Street Journal. Reference Link
December 10, 2014
11:12 EDTFBInstagram announces service now has over 300M users
Subscribe for More Information
09:36 EDTFBActive equity options trading
Subscribe for More Information
08:09 EDTFBFacebook management to meet with UBS
Subscribe for More Information
06:08 EDTBMYBristol-Myers partners with Ono Pharma and Kyowa Hakko Kirin for oncology trial
Subscribe for More Information
December 9, 2014
16:35 EDTBMYBristol-Myers raises dividend to 37c per share from 36c per share
Subscribe for More Information
16:00 EDTFBOptions Update; December 9, 2014
Subscribe for More Information
12:48 EDTFBFacebook volatility at low end of historic range
Subscribe for More Information
08:25 EDTBMYBristol-Myers data positive, says BMO Capital
Subscribe for More Information
December 8, 2014
13:32 EDTBMYPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
14:10 EDTBMYAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use